CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule ...
CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday. CTI will become a wholly ...
A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC). Shares of the commercial-stage biotech took a nearly 12% hit on the day, as investors ...
Vonjo will carry a wholesale acquisition cost of $19,500 a month, CTI executives said on a call with investors Tuesday. (Pixabay) It’s been a long and tortuous path to approval for CTI BioPharma’s ...
ST. LOUIS, Jan. 21, 2025 /PRNewswire/ -- CTI, the largest privately held AV integration and events provider in the U.S., has acquired Delta AV of Gresham, Oregon, adding the team's sterling reputation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results